Table 2. HAART-induced immunologic... | American Society of Hematology

Table 2.

HAART-induced immunologic improvement in 99 HIV-1–infected patients with different patterns of plasma viral load response

	Patterns of viral load response
	Responders^*	Transient responders^†	Nonresponders^‡
Number of patients (naive/ pretreated)	59/99 (24/35)	23/99 (9/14)	17/99 (1/16)
β2-microglobulin (mg/L)
at entry	4.07 ± 0.46	3.72 ± 0.19	4.59 ± 0.66
at 6 mos	3.23 ± 0.45^2-153	3.02 ± 0.15^2-153	3.74 ± 0.70^2-153
at 12 mos	3.09 ± 0.46^2-153	2.77 ± 0.15^2-153	3.48 ± 0.48^2-153
Memory CD4 cells/μL
at entry	105 ± 9	99 ± 17	82 ± 18
at 6 mos	189 ± 13^2-153	174 ± 20^2-153	144 ± 25^2-153
at 12 mos	204 ± 14^2-153	190 ± 19^2-153	156 ± 28^2-153
Naive CD4 cells/μL
at entry	49 ± 6	44 ± 8	28 ± 7
at 6 mos	69 ± 7^2-153	63 ± 9^2-153	51 ± 11^2-153
at 12 mos	95 ± 7^2-153	84 ± 10^2-153	68 ± 12^2-153
Number of patients with baseline CD8 cells < 1000/μL (naive/pretreated)	35/62 (13/22)	14/62 (7/8)	13/62 (1/12)
Memory CD8 cells/μL
at entry	465 ± 27	385 ± 59	396 ± 58
at 6 mos	774 ± 55^2-155	557 ± 38^2-155	608 ± 87^2-155
at 12 mos	769 ± 49^2-153	669 ± 44^2-153	698 ± 104^2-153
Naive CD8 cells/μL
at entry	85 ± 8	65 ± 11	64 ± 11
at 6 mos	118 ± 10^2-155	96 ± 14^2-155	101 ± 14^2-155
at 12 mos	144 ± 12^2-153	124 ± 16^2-153	131 ± 19^2-153

	Patterns of viral load response
	Responders^*	Transient responders^†	Nonresponders^‡
Number of patients (naive/ pretreated)	59/99 (24/35)	23/99 (9/14)	17/99 (1/16)
β2-microglobulin (mg/L)
at entry	4.07 ± 0.46	3.72 ± 0.19	4.59 ± 0.66
at 6 mos	3.23 ± 0.45^2-153	3.02 ± 0.15^2-153	3.74 ± 0.70^2-153
at 12 mos	3.09 ± 0.46^2-153	2.77 ± 0.15^2-153	3.48 ± 0.48^2-153
Memory CD4 cells/μL
at entry	105 ± 9	99 ± 17	82 ± 18
at 6 mos	189 ± 13^2-153	174 ± 20^2-153	144 ± 25^2-153
at 12 mos	204 ± 14^2-153	190 ± 19^2-153	156 ± 28^2-153
Naive CD4 cells/μL
at entry	49 ± 6	44 ± 8	28 ± 7
at 6 mos	69 ± 7^2-153	63 ± 9^2-153	51 ± 11^2-153
at 12 mos	95 ± 7^2-153	84 ± 10^2-153	68 ± 12^2-153
Number of patients with baseline CD8 cells < 1000/μL (naive/pretreated)	35/62 (13/22)	14/62 (7/8)	13/62 (1/12)
Memory CD8 cells/μL
at entry	465 ± 27	385 ± 59	396 ± 58
at 6 mos	774 ± 55^2-155	557 ± 38^2-155	608 ± 87^2-155
at 12 mos	769 ± 49^2-153	669 ± 44^2-153	698 ± 104^2-153
Naive CD8 cells/μL
at entry	85 ± 8	65 ± 11	64 ± 11
at 6 mos	118 ± 10^2-155	96 ± 14^2-155	101 ± 14^2-155
at 12 mos	144 ± 12^2-153	124 ± 16^2-153	131 ± 19^2-153

HAART, highly active antiretroviral therapy; HIV-1, human immunodeficiency virus type 1.

Patients who had a plasma viral load decrease (ie, <1000 or 3 log₁₀ Eq copies/mL) through the 12 mos of the study.

†

Patients who had an initial plasma viral load decrease (ie, <1000 or 3 log₁₀ Eq copies/mL) after 2 mos of HAART but had a viral load reincrease (ie, 1000 or 3 log₁₀ Eq copies/mL) at 8 to 12 mos of treatment.

‡

Patients whose plasma viral load remained 1000 or 3 log₁₀ Eq copies/mL throughout the 12 mos of the study.

F2-153

P value (Wilcoxon) < .01;

F2-155

P < .05 compared with baseline value.

View Large

This Feature Is Available To Subscribers Only